熱門資訊> 正文

Larimar Therapeutics GAAP每股收益为-0.34美元

2024-08-07 21:19

Larimar Therapeutics press release (NASDAQ:LRMR): Q2 GAAP EPS of -$0.34.
As of June 30, 2024, the Company had cash, cash equivalents and marketable securities totaling $226.1 million,

More on Larimar Therapeutics

Larimar Therapeutics: More Data Still Needed
Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
Larimar's Friedreich's ataxia asset nomlabofusp chosen for FDA accelerated program
Biggest stock movers today: ZIM, XPEV, PANW, GOTU, and more
Seeking Alpha’s Quant Rating on Larimar Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。